MedicaidPrior AuthMedium impact
KMAP BULLETIN: Brand Product Exemption Updates
Kansas Medicaid (KanCare)·KS · Endocrinology, Psychiatry, Pediatrics +3 more·Provider Bulletin
Effective date
Jan 1, 2024
We identified it
Jun 21, 2026
Summary
Kansas Medicaid (KMAP) has updated brand drug exemptions effective retroactively to January 1, 2024. Four brand medications (Daytrana, Lantus, Vyvanse, Humira) are now exempt from Brand Medical Necessity prior authorization requirements, with Humira's exemption ending October 1, 2025.
Action Required
Immediately: Billing team must update prior authorization workflows to remove Brand Medical Necessity PA requirements for Daytrana, Lantus, Vyvanse, and Humira for Kansas Medicaid patients. Set system reminder that Humira exemption expires October 1, 2025, and PA requirements will resume. Verify with individual KanCare MCOs for their specific implementation dates as they may vary from state policy dates.